Incyte

Incyte INCY Stock

$116.23   -1.328525%
Add to favorites
Market Cap
$23.69B
LOW - HIGH [24H]
$115.50 - $117.98
VOLUME [24H]
$340.50K
P/E Ratio
59.30
Earnings per share
$1.96
ISIN
US45337C1027
Price   Prediction

Incyte Price Chart

Sorry, that's all we've gotfor now...

Incyte (INCY) stock price today is 116.24 USD on Tech Market Large (-1.33% on the day). Updated .

Incyte INCY Financial and Trading Overview

Incyte stock price 116.24 USD
Previous Close 120.27 USD
Open 119.95 USD
Bid 108.68 USD x 200
Ask 128.17 USD x 200
Day's Range 118.05 - 121.43 USD
52 Week Range 89.25 - 132.6 USD
Volume 2.25M USD
Avg. Volume 1.61M USD
Market Cap 24.27B USD
Beta (5Y Monthly) 0.784
PE Ratio (TTM) 60.7602
EPS (TTM) 1.96 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 132.25 USD

INCY Valuation Measures

Enterprise Value 20.46B USD
Trailing P/E 60.7602
Forward P/E 13.814535
PEG Ratio (5 yr expected) 10.82
Price/Sales (ttm) 4.038497
Price/Book (mrq) 4.30534
Enterprise Value/Revenue 3.403
Enterprise Value/EBITDA 10.051

Trading Information

Incyte Stock Price History

Beta (5Y Monthly) 0.784
52-Week Change 15.76%
S&P500 52-Week Change 12.07%
52 Week High 132.6 USD
52 Week Low 89.25 USD
50-Day Moving Average 119.05 USD
200-Day Moving Average 109.02 USD

INCY Share Statistics

Avg. Volume (3 month) 1.61M USD
Avg. Daily Volume (10-Days) 1.5M USD
Shares Outstanding 203.83M
Float 171.56M
Short Ratio 5.54
% Held by Insiders 1.87%
% Held by Institutions 102.02%
Shares Short 10.65M
Short % of Float 8.87%
Short % of Shares Outstanding 5.21%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 6.71%
Operating Margin (ttm) 32.22%
Gross Margin 56.01%
EBITDA Margin 33.86%

Management Effectiveness

Return on Assets (ttm) 17.78%
Return on Equity (ttm) 7.83%

Income Statement

Revenue (ttm) 6.01B USD
Revenue Per Share (ttm) 30.04 USD
Quarterly Revenue Growth (yoy) 14.00%
Gross Profit (ttm) 3.37B USD
EBITDA 2.04B USD
Net Income Avi to Common (ttm) 403.41M USD
Diluted EPS (ttm) 1.96
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 3.85B USD
Total Cash Per Share (mrq) 18.91 USD
Total Debt (mrq) 37.41M USD
Total Debt/Equity (mrq) 0.66 USD
Current Ratio (mrq) 3.84
Book Value Per Share (mrq) 27.661

Cash Flow Statement

Operating Cash Flow (ttm) 744.99M USD
Levered Free Cash Flow (ttm) 1.29B USD

Profile of Incyte

Country United States
State DE
City Wilmington
Address 1801 Augustine Cut-Off
ZIP 19803
Phone 302 498 6700
Website https://www.incyte.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 2844

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Q&A For Incyte Stock

What is a current INCY stock price?

Incyte INCY stock price today per share is 116.24 USD.

How to purchase Incyte stock?

You can buy INCY shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Incyte?

The stock symbol or ticker of Incyte is INCY.

Which industry does the Incyte company belong to?

The Incyte industry is Biotechnology.

How many shares does Incyte have in circulation?

The max supply of Incyte shares is 203.83M.

What is Incyte Price to Earnings Ratio (PE Ratio)?

Incyte PE Ratio is 59.30357000 now.

What was Incyte earnings per share over the trailing 12 months (TTM)?

Incyte EPS is 1.96 USD over the trailing 12 months.

Which sector does the Incyte company belong to?

The Incyte sector is Healthcare.

Incyte INCY included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24201.34 USD —
-0.94
4.68B USD — 24005.47 USD — 24939.62 USD — — 4.68B USD —
us S&P 500 (Yahoo.com) GSPC US 7246.84 USD —
-1.05
1.47B USD — 7193.83 USD — 7415.64 USD — — 1.47B USD —
us S&P 500 INDEX SPX US 7280.07 USD —
-0.59
1.4B USD — 7193.83 USD — 7415.64 USD — — 1.4B USD —
us Dow Jones U.S. Biotechnology In DJUSBT US 3888.92 USD —
-0.27
51.92M USD — 3856.79 USD — 3919.64 USD — — 51.92M USD —
us US Tech Next Generation 100 Inde NGX US 1686.49 USD —
-0.59
— — 1673.01 USD — 1717.15 USD — — — —
us US Tech Biotechnology NBI US 6965.89 USD —
-0.08
— — 6905.76 USD — 7033.67 USD — — — —
us US Tech Health Care IXHC US 1317.49 USD —
-0.52
— — 1309.03 USD — 1333.62 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7603.91 USD —
-0.19
— — 7546.09 USD — 7685.86 USD — — — —
us US Tech US Smart Pharmaceuticals NQSSPH US 2246.21 USD —
-1.59
— — 2233.15 USD — 2284.66 USD — — — —
us US Tech Global Select Market Com NQGS US 11949.46 USD —
-0.71
— — 11825.17 USD — 12288.24 USD — — — —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us The Capital Strength Index NQCAPST US 3720.9 USD —
-1.37
— — 3704.61 USD — 3764.15 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Composite Total Return XCMP US 29950.1 USD —
-0.8
— — 29671.6 USD — 30826.03 USD — — — —
us US Tech Q-50 NXTQ US 1179.02 USD —
-0.05
— — 1168.83 USD — 1196.31 USD — — — —
us US Tech US Price Setters Index NQPRCE US 3119.2 USD —
-1.21
— — 3101.8 USD — 3161.04 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3605.34 USD —
-0.97
— — 3577.02 USD — 3690.74 USD — — — —
us The Capital Strength Net Total NQCAPSTN US 4464.35 USD —
-1.37
— — 4444.79 USD — 4516.57 USD — — — —
$2.17T
Total marketcap
$71.79B
Total volume
BTC 58.07%   •   ETH 9.95%
Dominance
Select currency